Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members

Rhea-AI Summary

Certara has appointed Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021, increasing the board to eleven members. Killefer brings over 30 years of executive experience in pharmaceuticals and healthcare, previously serving as a director at McKinsey & Company. Collins, with over 40 years in biotechnology, was CEO at Editas Medicine, where she led significant advancements in gene editing. Both directors aim to leverage their expertise to enhance Certara's drug discovery and development processes.

Positive

• Nancy Killefer and Cynthia Collins bring extensive corporate experience, enhancing board leadership.
• Killefer's experience includes significant roles in pharmaceuticals and as a director at McKinsey & Company.
• Collins has a proven track record of scaling biotechnology companies, including Editas Medicine.

Negative

• None.

PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021. The two additional appointments increase the company’s board of directors to eleven members.

“It’s truly a pleasure to welcome Nancy and Cynthia to the board of directors,” said Sheri McCoy, board chairman. “Their wealth of knowledge and extensive corporate board and leadership experience will be essential to us and no doubt strengthen our guidance of Certara.”

Ms. Killefer brings more than three decades of executive experience across the pharmaceutical, healthcare and technology sectors, most recently serving as director at McKinsey & Company until her retirement in 2013. She has also served in the public sector, specifically the United States Department of the Treasury as the assistant secretary for Management, chief financial officer and chief operating officer. Ms. Killefer is currently a member of the boards of Cardinal Health, Inc., Natura & Company, and Facebook, Inc.

Ms. Collins is a biotechnology industry veteran with more than 40 years of experience in gene and cell medicines and growing biotech companies. Most recently, she was the Chief Executive Officer of Editas Medicine, a gene editing biotechnology company, which experienced significant growth under her leadership, including dosing the first patient in the world with an in vivo gene edited therapy. Before Editas, Ms. Collins was CEO at several life sciences companies, including Human Longevity, GenVec and Sequoia Pharmaceuticals.  Ms. Collins is currently a member of the board of DermTech, Inc.

“By providing model-informed insights into the safety and efficacy of novel drugs, Certara’s biosimulation software transforms how medicines are made across therapeutic areas,” said Ms. Killefer. “I look forward to helping the company accelerate drug discovery and development for the benefit of all patients.”

“Certara’s track record of scientific innovation and thought leadership is inspiring,” said Ms. Collins.  “I am excited to bring my experience in scaling biotechnology companies to the Certara board and help steward the company towards continued success.”

About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:

David Deuchler
Gilmartin Group
ir@certara.com 

Media Contact:

Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com 

FAQ

Who were appointed to Certara's board of directors on August 1, 2021?

Nancy Killefer and Cynthia Collins were appointed to Certara's board of directors.

What relevant experience does Nancy Killefer have for Certara?

Nancy Killefer has over 30 years of experience in pharmaceuticals and healthcare, including roles at McKinsey & Company and the U.S. Department of the Treasury.

What is Cynthia Collins' background in the biotechnology industry?

Cynthia Collins has over 40 years of experience, most notably as CEO of Editas Medicine, where she oversaw significant advancements in gene editing.

How many members are now on Certara's board of directors?

The appointment of Killefer and Collins increases Certara's board to eleven members.

What are the expected contributions of the new board members to Certara?

Both Killefer and Collins are expected to leverage their extensive industry experience to enhance Certara's drug discovery and development strategies.